Media headlines about Amedica (NASDAQ:AMDA) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amedica earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.0495433251866 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- ETFs with exposure to Amedica Corp. : December 5, 2017 (finance.yahoo.com)
- Amedica (AMDA) Rating Lowered to Sell at ValuEngine (americanbankingnews.com)
- Ensnaring Stock- Amedica Corporation (NASDAQ:AMDA) a Medical Appliances & Equipment Company – The Stock Street (press release) (thestreetpoint.com)
- Amedica Receives Positive Nasdaq Listing Decision Nasdaq:AMDA – GlobeNewswire (press release) (globenewswire.com)
- Amedica Corp. :AMDA-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017 (finance.yahoo.com)
Amedica (AMDA) opened at $3.18 on Wednesday. Amedica has a 1 year low of $2.95 and a 1 year high of $9.24.
Amedica (NASDAQ:AMDA) last released its earnings results on Tuesday, November 21st. The medical equipment provider reported ($0.93) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.94) by $0.01. The firm had revenue of $2.96 million for the quarter. Amedica had a negative net margin of 87.49% and a negative return on equity of 77.71%. research analysts forecast that Amedica will post -5.64 earnings per share for the current year.
AMDA has been the topic of a number of research analyst reports. Ladenburg Thalmann Financial Services downgraded shares of Amedica from a “buy” rating to a “neutral” rating in a research report on Monday, November 27th. Maxim Group downgraded shares of Amedica from a “buy” rating to a “hold” rating in a research report on Monday, September 25th. Finally, ValuEngine raised shares of Amedica from a “sell” rating to a “hold” rating in a research report on Friday, November 10th.
Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty.
Receive News & Ratings for Amedica Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica Co. and related companies with MarketBeat.com's FREE daily email newsletter.